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overweight and who had breastfeeding more than 6 months, the risk of developing 
bronchial asthma was three times higher in  future life. 
Conclusions. 1. Overweight at birth is associated with a high risk of developing 
bronchial asthma in children (RR – 3,17 (95% CI 0,98-10,1)). 
2. The presence of breast-feeding up to 6 months and  longer was associated with the 
risk of developing bronchial asthma in children with a sensitivity of 84,9% and a 
specificity of 88,8%. 
3. Children who had breastfeeding more than 6 months is determined by the high risk 
of implementing bronchial asthma, which should cause particular disturbance to 
district pediatricians for the timely detection and initiation of treatment of the disease. 
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Purpose of the study. To increase the controllability of asthma in school-age 
children by using Nucleinate as a component in the complex therapy. 
Material and methods. 45 school-age children with asthma in the remission period 
were comprehensively examined in the pulmonology department of the Chernivtsi 
Regional Children's Clinical Hospital. Nucleinat was taken at a dose of 0.25 g in day 
for 21 days in the complex of basic therapy prepared in accordance with the 
International Consensus for the treatment of asthma in children. This clinical group 
included 31 boys (68.8%) and 14 girls (31.1%), and the average age of patients was 
11.8 ± 0.5 years. Mild asthma was observed in 4 patients (8,9 ± 4,2%), moderate 
asthma in 26 children (66,7 ± 7,4%) and severe - in 15 patients (33,3 ± 7,0%). All 
children underwent a baseline assessment of asthma control with the help of a survey 
before and after the course of anti-inflammatory therapy. The function of external 
respiration was assessed according to the indices of FEV1 (forced expiratory volume 
for the first second) and PEF (peak expiratory flow rate). At the same time, the above 
indicators were estimated as follows: if the FEV1 and the PEF were more than 90% 
of the norm - 0, 80-89% - 1, 70-79% - 2, 60-69% - 3 and less than 60% - 4 points. 
The effectiveness of the control therapy was analyzed according to the sum dynamics 
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of the spirographic examination, in such a way that, given the deterioration in the 
control of the BA, the score increased. All patients were assessed by hypersensitivity 
of the respiratory tract using the MicroLab portable calibration spirograph from 
Micro Medical. Hypersensitivity of the bronchi was assessed according to the 
provoking dose of histamine, which reduces the forced expiratory volume in the first 
second by 20% (PC20H), and the cumulative dose (PD20H) using serial dilutions of 
histamine. The obtained results were analyzed by variational statistics methods using 
statistical software StatSoft Statistica v5.0. 
Results and discussion. It was noted that after treatment a part of children who 
needed frequent use of short-acting β2-agonists (an average of 4-7 doses per week) 
decreased. So, before the start of treatment, the need was indicated in 46.6% of 
patients, and after only 22.2% of patients (P <0.05). At the same time, school-age 
children had a significant decrease in the score of the clinical state of children (from 
15 ± 0.8 points before treatment to 11.1 ± 0.8 points after (p <0.05)). In our opinion, 
the results indicated that the introduction of Nucleinate into the complex of anti-
inflammatory therapy of asthma caused an increase in the level of disease control. 
After treatment in children, a decrease in the bronchial hypersensitivity in the form of 
an increase in the provoking and cumulative doses of histamine by 2.6 times was 
revealed. So, before using the drug, provoking and cumulative doses of histamine 
were 1.02 ± 0.2 mg / ml and 0.22 ± 0.04 mg, and after treatment - 3.6 ± 1.3 mg / ml 
and 0.8 ± 0.3 mg, respectively (p <0.05). Simultaneously after treatment, the 
hypersensitivity of the respiratory tract decreased in 57.8% of patients. In our 
opinion, the results can be explained by a decrease in the inflammatory component of 
bronchial hypersensitivity under the influence of complex treatment. 
Conclusions: 1. The use of Nucleinate in the complex of anti-inflammatory therapy 
reliably allows to achieve a better level of bronchial asthma control in school-age 
children. 2. The use of Nucleinate in the complex of basic therapy of bronchial 
asthma in children can reliably reduce bronchial hypersensitivity due to a likely 
decrease in the activity of the inflammatory process of the respiratory tract. 
 
 
 
 
